This retrospective analysis reviewed all the incident stage I-III HER2-positive breast cancer patients who received neoadjuvant TCH in three institutions. Overall, TCH was well tolerated, with low rates of grade 3-4 adverse events, and neither late toxicities nor cardiac dysfunctions were reported.
Breast Cancer Res Treat